Medis El to reacquire US rights to CellScan:
This article was originally published in Clinica
Israeli diagnostic company Medis El has the option to reacquire the US distribution rights to CellScan under an agreement with US shareholder Cell Diagnostics (CDI). Medis will receive $500,000 from CDI on July 1st, as the first repayment of a $2.5 million note. Medis will cancel the unpaid $2 million if it exercises the option to CellScan. Medis says the US rights will be an asset in its search for an international marketing partner for the cancer screening system.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.